Amneal Pharmaceuticals, Inc.

Kashiv BioSciences and its commercialization partners have announced positive topline data from a Phase III confirmatory trial investigating the omalizumab biosimilar rival to Genentech/Novartis’ Xola

Whit Bernard’s journey to becoming CEO of New York obesity-focused biotech Metsera began in an unlikely place: studying punk rock and community choirs in Soviet-era Latvia. As a Fulbright Scholar in m

For Amneal, “Made in America” isn’t just a label. It is heritage, a cornerstone of its strategy, and a competitive advantage. Or at least that is how co-CEOs Chirag and Chintu Patel tried to reassure

Viatris has agreed to pay up to $335m as part of a nationwide settlement resolving opioid-related claims by US state and local governments, but admitted no wrongdoing. Under the recently announced fra